Table 1.
Upfront treatment regimens
| Upfront regimen | % receiving RT | |
|---|---|---|
| ABVE-PC | 37 (55%) | 17 (46%) |
| ABVD | 12 (18%) | 1 (8%) |
| OEPA-COPDAC | 8 (12%) | 4 (50%) |
| Stanford V | 3 (4%) | 7 (70%) |
| BEACOPP | 2 (3%) | |
| BV-AVE-PC | 2 (3%) | |
| Nivolumab-AVD | 1 (1%) | |
| Other | 2 (3%) | |
ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; AVD, doxorubicin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide, cyclophosphamide, vincristine, prednisone, procarbazine; BV-AVE-PC, brentuximab vedotin, doxorubicin, vincristine, etoposide, prednisone, cyclophophamide; OEPA-COPDAC, vincristine, etoposide, prednisone, doxorubicin, cyclophosphamide, vincristine, prednisone, dacarbazine; Stanford V, mechlorethamine, etoposide, adriamycin, bleomycin, vincristine, vinblastine, prednisone.